Search Results
Your search for ,iII matches 9601 pages
Showing 1951 - 2000Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Adjuvant Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation in Early Breast Cancer: 10 Year Outcomes of Phase III Study
As reported in The Lancet Oncology by Vratislav Strnad, MD, PhD, of University Hospital Erlangen and Comprehensive Cancer Center Erlangen, Germany, and colleagues, 10-year outcomes in a phase III GEC-ESTRO (Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology) trial...
Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of...
Rahul Aggarwal, MD, on Prostate Cancer: Phase III Data on Apalutamide and Androgen Deprivation in Relapsed Disease
Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
GLOW Trial: Zolbetuximab Plus CAPOX Extends Survival in Gastric Cancer Subtype
First-line treatment with zolbetuximab in combination with capecitabine and oxaliplatin (CAPOX) extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive/HER2-negative locally advanced or metastatic gastric adenocarcinoma, according to results of the GLOW trial reported by Xu et...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Study Examines Effect of Physical Activity on Recurrence in Patients Previously Treated for Colorectal Cancer
Researchers have found that postoperative physical activity was associated with improved disease-free survival among patients previously treated for stage III colorectal cancer, according to a novel study published by Brown et al in the British Journal of Sports Medicine. “With March being National ...
First-Line Therapy of Metastatic Colon Cancer
This is Part 3 of The Evolving Targeted Treatment Landscape for Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. John Strickler, Stacey A. Cohen, and Harshabad Singh discuss the first-line treatment of...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Isolated Hepatic Perfusion May Improve Response and Survival Among Patients With Metastatic Uveal Melanoma
An advanced surgical therapy may be more efficacious than conventional treatments for patients with uveal melanoma that has spread to the liver, according to results from the phase III SCANDIUM trial published by Bagge et al in the Journal of Clinical Oncology. Infusing the liver with high doses of ...
Active Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer: 15-Year Outcomes in the UK ProtecT Trial
As reported in The New England Journal of Medicine by Freddie C. Hamdy, FRCS(Urol), FMedSci, and colleagues, 15-year follow-up of the UK phase III ProtecT trial has shown no significant difference in prostate cancer mortality with active monitoring, surgery, or radiotherapy for patients with...
Laparoscopy-Assisted vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Relapse-Free Survival at 5 Years
As reported in JAMA Surgery by Etoh et al, 5-year follow-up of the Japanese phase II/III JLSSG0901 trial has shown noninferiority in relapse-free survival with laparoscopic-assisted distal gastrectomy vs open distal gastrectomy in patients with locally advanced gastric cancer. Study Details In the...
Low-Dose Tamoxifen to Prevent Recurrence in Patients With Breast Noninvasive Neoplasia: 10-Year Follow-up of TAM-01 Trial
As reported in the Journal of Clinical Oncology by Lazzeroni et al, the 10-year follow-up of the Italian phase III TAM-01 trial has shown that 3 years of low-dose tamoxifen vs placebo continued to be associated with a reduced risk of recurrence of invasive breast cancer or ductal carcinoma in situ...
Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer
In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer.1 Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
Magrolimab Plus Azacitidine in Higher-Risk Myelodysplastic Syndromes
In a phase Ib trial (5F9005) reported in the Journal of Clinical Oncology, David A. Sallman, MD, and colleagues found that the combination of magrolimab and azacitidine showed activity in previously untreated patients with intermediate- to very high–risk myelodysplastic syndromes (MDS). As stated...
When Can You Stop Lenalidomide Maintenance in Myeloma?
A study aimed at determining the optimal duration of lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma has not answered that question, per se, but has yielded some hints that may inform future clinical trials. The follow-up analysis of the UK NCRI Myeloma XI...
Health-Related Quality of Life in the KEYNOTE-826 Trial in Patients With Cervical Cancer
In an analysis from the phase III KEYNOTE-826 trial reported in The Lancet Oncology, Bradley J. Monk, MD, and colleagues found that the addition of pembrolizumab to chemotherapy with or without bevacizumab did not adversely affect health-related quality of life in patients with persistent,...
Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet, You et al found that hyperfractionated vs standard-fractionation intensity-modulated radiotherapy (IMRT) was associated with reduced late severe radiotherapy complications and improved overall survival in patients with locally advanced, recurrent ...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
Unique Challenges of Cancer Care in India
In this installment of The ASCO Post’s Global Oncology, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Rajendra Toprani, MBBS, MS, MCh, Head of the Department of Head and Neck Surgical Oncology at HCG Cancer Centre, Ahmedabad, India. Dr. Toprani’s areas of interest include oral,...
PhALLCON Study: Ponatinib Superior to Imatinib in Combination With Chemotherapy in Newly Diagnosed, Ph-Positive ALL
Ponatinib appears to be a more effective tyrosine kinase inhibitor than imatinib in newly diagnosed, Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when combined with reduced-intensity chemotherapy, according to data presented during the ASCO Plenary Series: February 2023...
First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the...
Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
In heavily pretreated patients with metastatic colorectal cancer who have microsatellite-stable tumors, the novel combination of the monoclonal antibodies botensilimab and balstilimab showed clinical activity, producing durable responses and an estimated 63% overall survival rate at 12 months,...
Expert Point of View: David Wang, MD, PhD
David Wang, MD, PhD, Associate Professor of Internal Medicine at UT Southwestern Medical Center and VA North Texas Health Care System, was invited to discuss the CheckMate 649 and RATIONALE 305 studies. “CheckMate 649 was the first randomized controlled trial to demonstrate a significant survival...
Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Inhibition Plus Chemotherapy in Gastric Cancer
Two phase III trials evaluating the addition of drugs targeting PD-1 to chemotherapy—RATIONALE 305 and CheckMate 649—confirmed the benefit of this approach as first-line therapy for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, in findings presented at the 2023 ASCO GI...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
With longer-term follow-up, adjuvant nivolumab continued to demonstrate improved disease-free survival, non–urothelial tract recurrence–free survival, and distant metastasis–free survival vs placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after surgery,...
Cancer Stage and Receptor Status May Indicate Risk of Disease Recurrence in Breast Cancer Survivors
Investigators have found that in breast cancer survivors, the cancer’s stage and receptor status may help clinicians predict whether and when cancer might recur after initial treatment, according to a new study published by Neuman et al in Cancer. Study Methods and Results In the new study, the...
First-Line Lenvatinib/Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Extended Follow-up of the CLEAR Trial
As reported in The Lancet Oncology by Toni K. Choueiri, MD, and colleagues, extended follow-up of the phase III CLEAR trial has shown maintained progression-free and overall survival benefits with first-line lenvatinib plus pembrolizumab vs sunitinib in patients with advanced clear cell renal cell...
Neoadjuvant Plus Adjuvant vs Adjuvant Pembrolizumab in Advanced Melanoma
In the phase II SWOG Cancer Research Network S1801 trial reported in The New England Journal of Medicine, Sapna P. Patel, MD, and colleagues found that neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival vs adjuvant pembrolizumab alone in patients with stage IIIB to...
Prognosis of HER2-Low vs HER2-Negative Breast Cancer
In an analysis of National Cancer Database data reported in JAMA Oncology, Peiffer et al found “minimal prognostic differences” between HER2-low vs HER2-negative breast cancer, with the findings not supporting classification of HER2-low disease as a distinct disease subtype. Study Details The...
Addition of Pembrolizumab to Pemetrexed/Platinum in the First-Line Treatment of Metastatic Nonsquamous NSCLC: 5-Year Outcomes in the KEYNOTE-189 Study
As reported in the Journal of Clinical Oncology by Marina C. Garassino, MD, and colleagues, 5-year follow-up in the phase III KEYNOTE-189 trial has shown maintained progression-free and overall survival benefits with the addition of pembrolizumab to pemetrexed and platinum chemotherapy in the...
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: Outcomes by Disease Volume and Risk Status in the ARASENS Trial
In an analysis from the phase III ARASENS trial reported in the Journal of Clinical Oncology, Maha Hussain, MD, FACP, FASCO, and colleagues found that the addition of darolutamide to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival in subgroups of patients...
Association of Immune-Related Adverse Events With Overall Survival in Patients Receiving Atezolizumab-Containing Therapy for Metastatic Nonsquamous NSCLC
In a pooled analysis reported in JAMA Oncology, Mark A. Socinski, MD, and colleagues found that patients with nonsquamous non–small cell lung cancer (NSCLC) receiving atezolizumab who had grade 1 or 2 immune-related adverse events in clinical trials had improved overall survival vs those with no...
